Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • Carcinoma
  • Colonic Neoplasms
  • Cyclophosphamide
  • Cytochrome P-450 CYP2B1
  • Genetic Therapy
  • Herpesvirus 1, Human
  • Liver Neoplasms
  • Transgenes

abstract

  • The rRp450 mutant HSV-1 is highly oncolytic against colon carcinoma cells both in vitro and in vivo. rRp450 displays preferential replication in colon carcinoma cells compared to normal hepatocytes. Activation of cyclophosphamide by the p450 transgene augmented the anti-neoplastic effects of rRp450 without simultaneously decreasing viral replication. Oncolysis induced by HSV-1 replication combined with cyclophosphamide prodrug activation warrants further investigation as a potential therapy for colon carcinoma liver metastases.

publication date

  • September 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.10776

PubMed ID

  • 12209705

Additional Document Info

start page

  • 1171

end page

  • 81

volume

  • 95

number

  • 5